Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatology. Oct 27, 2011; 3(10): 262-264
Published online Oct 27, 2011. doi: 10.4254/wjh.v3.i10.262
Published online Oct 27, 2011. doi: 10.4254/wjh.v3.i10.262
Budd-Chiari syndrome management: Lights and shadows
Andrea Mancuso, Epatologia e Gastroenterologia, Ospedale Niguarda Ca’ Granda, Milano 20162, Italy
Author contributions: Mancuso A contributed solely to this work.
Correspondence to: Andrea Mancuso, MD, Epatologia e Gastroenterologia, Ospedale Niguarda Ca’ Granda, Piazza Maggiore 3, Milano 20162, Italy. mancandrea@libero.it
Telephone: +39-2-64442111 Fax: +39-2-64442895
Received: January 31, 2011
Revised: July 19, 2011
Accepted: September 20, 2011
Published online: October 27, 2011
Revised: July 19, 2011
Accepted: September 20, 2011
Published online: October 27, 2011
Abstract
Budd-Chiari syndrome (BCS) is a rare disease whose management should follow a step by step strategy. Anticoagulation and medical therapy should be the first line treatment. Revascularization or TIPS are indicated in case of no response to medical therapy. OLT should be indicated as a rescue therapy and anticoagulation be started soon after OLT. However, no clear indication can actually be given about the timing of different treatments. Moreover, there is some concern about treatment of some subgroup of patients, especially regarding the risk of recurrence after liver transplantation. The topic of this paper is to critically review the actual knowledge of BCS management.
Keywords: Budd-Chiari syndrome, Management, Liver transplantation